Tradestie Institutional Equity Comparison Engine

BCRX vs CVM โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BCRX Overall Edge

BCRX Captures Institutional Edge (4โ€“0 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BioCryst Pharmaceuticals Inc (BCRX) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, BCRX trades at 8.9x Forward P/E with 48.8% operating margin (+13.1% YoY revenue) versus CVM at 23.0x Forward P/E and 0.0% operating margin (-62.7% YoY). In options structure, BCRX sits in BREAKDOWN (12th %ile IV; Dealer Gamma Walls on Pro) against CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner BCRX
BCRX 8.9x vs CVM 23.0x Fwd P/E
Growth & Margin Winner BCRX
Op Margin 48.8% vs 0.0% ยท YoY +13.1% vs -62.7%
Momentum & Technical Winner BCRX
1Y +9.1% vs -77.5% ยท 52W Pos 26% vs 10%
Options & Structure Winner BCRX
BREAKDOWN (12th %ile IV) vs BREAKDOWN (N/A IV)
BCRX NASDAQ
BioCryst Pharmaceuticals Inc
Biological Products, (No Disgnostic Substances)
$7.53
-1.05% 1D
Market Cap $1.9B
1M Return -3.34%
1Y Return +9.13%
Forward P/E 8.9x
Unified AI Score
43.3 / 100 HOLD
Tech 24.0 Fund 59.0 Flow 67.0 Mom 68.9
CVM NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap $20.9M
1M Return -11.17%
1Y Return -77.48%
Forward P/E 23.0x
Unified AI Score
56.6 / 100 HOLD
Tech 60.0 Fund 54.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BCRX +9.13% CVM -77.48% Spread: +82.34 pp (BCRX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period BCRX Revenue CVM Revenue BCRX Op. Margin CVM Op. Margin Margin Edge
FY2018 $20M N/A -456.2% N/A BCRX
FY2019 $50M N/A -203.7% N/A BCRX
FY2020 $20M N/A -981.1% N/A BCRX
FY2021 $160M N/A -113.1% N/A BCRX
FY2022 $270M N/A -54.8% N/A BCRX
FY2023 $330M N/A -31.3% N/A BCRX
FY2024 $450M N/A -0.6% N/A BCRX
FY2025 $870M N/A 39.0% N/A BCRX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BCRX (7) vs CVM (3)
Institutional Metric BCRX CVM Criterion Row Winner
Market Capitalization Scale $1.9B $20.9M Larger Scale BCRX
Trailing P/E Ratio Valuation 13.0x 23.0x Lower Multiple BCRX
Forward P/E Ratio Valuation 8.9x 23.0x Lower Multiple BCRX
Revenue Growth (YoY) Growth +13.1% -62.7% Higher Growth BCRX
Operating Margin (TTM) Profitability 48.8% 0.0% Higher Margin BCRX
Net Profit Margin Profitability -37.4% 0.0% Higher Margin CVM
Return on Equity (ROE) Capital Efficiency -1925.4% -252.5% Higher ROE CVM
52-Week Range Position Momentum 26% ($6โ€“$11) 10% ($1โ€“$8) Stronger Trend BCRX
Beta / 30D Volatility Risk Regime 0.77ฮฒ ยท 42% Vol 0.65ฮฒ ยท 120% Vol Lower Realized Risk BCRX
Unified Institutional Score Composite Signal 43.3 / 100 (HOLD) 56.6 / 100 (HOLD) Higher Composite CVM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BCRX vs CVM Buy Guide
BCRX BREAKDOWN
92d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 12th %ile
IV Regime Compressed (<25th %ile)
Live BCRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CVM BREAKDOWN
29d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CVM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BCRX nor CVM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.